Related Experiment Video
Updated: Oct 29, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
India's biosimilar reform and the global shift away from redundant clinical trials
Shambo Samrat Samajdar1, Noor Husain2, Harihar Dikshit3
1Allergy-Asthma Therapeutics Specialty Clinic, Kolkata, West Bengal, India.
Abstract:
India's 2025 draft guidelines on biosimilars mark an important change in how these medicines are regulated. The new approach focuses more on laboratory data, such as analytical and pharmacokinetic results, and less on large clinical trials. This is in line with current global thinking from agencies such as the European Medicines Agency and the World Health Organization. The commentary explains what the new guidelines mean, how they compare with past rules, and what challenges may arise during implementation. It also highlights India's chance to become a leader in global biosimilar access, especially for low- and middle-income countries. For this reform to succeed, strong systems, clear guidance, and proper training will be essential.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Bioequivalence studies: Biowaivers
Clinical Trials: Overview
Bioequivalence of Drugs: Drugs with Multiple Indications
Bioequivalence: Overview
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
